These results suggested that PAMs in therapeutic mAb-treated piglets might be activated by pGM-CSF, aligning with observed reductions of both pneumonia incidence and intracellular PRRSV-RNA levels. This evidence concerns the gene CSF1 and susceptibility to pneumonia measurement.